NCT03216525 Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
| NCT ID | NCT03216525 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Brigham and Women's Hospital |
| Condition | Bladder Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 136 participants |
| Start Date | 2018-10-01 |
| Primary Completion | 2023-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 136 participants in total. It began in 2018-10-01 with a primary completion date of 2023-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To determine if Alvimopan during open or robotic radical cystectomy with urinary diversion results in quicker return of bowel function (GI-2 recovery = time to upper \[first toleration of solid food\] and lower \[first bowel movement\] gastrointestinal recovery) compared to placebo.
Eligibility Criteria
Inclusion Criteria: * Patients undergoing radical cystectomy and urinary diversion via open or robotic approach. * Man or woman between the ages of 18 and 85. * American Society of Anesthesiologists (ASA) Physical Status Score of class 1-4 * Ileal conduit or ileal neobladder urinary diversion * Able to understand the study procedures, agreed to participate in the study program, and voluntarily provided informed consent Exclusion criteria: * Patients who met any of the following criteria were excluded from participating in the study: * Scheduled for a partial cystectomy * Previous total colectomy, gastrectomy, or gastric bypass, or functional colostomy or ileostomy * More than three doses of opioids (oral or parenteral) within 7 days before the day of surgery * Chemotherapy for bladder cancer within 1 month of scheduled surgery; prior neoadjuvant chemotherapy allowed. * Pregnant (identified by a positive serum pregnancy test administered after the initial screening process and before the commencement of study activities) or lactating, or not postmenopausal (no menses for at least 1 year) and of childbearing potential and not using an accepted method of birth control (i.e, surgical sterilization; intrauterine contraceptive device; oral contraceptive, diaphragm, or condom in combination with contraceptive cream, jelly, or foam; or abstinence) (Participants will be asked to use birth control for the entire study and for at least 2 weeks after the last dose of study drug.) * Participated in another investigational drug or medical device study within 30 days of surgery or planning to be enrolled in another investigational drug or medical device study or any study in which active patient participation was required outside normal hospital data collection during the course of this study * Clinically significant laboratory abnormalities at screening that would have resulted in the cancellation of surgery * Using illicit drugs or abusing alcohol * History of previous surgeries, illness, or behavior (eg, depression, psychosis) that in the opinion of the investigator might have confounded the study results or might have posed additional risk in administering the study procedures * Patients with severe dementia (as determined from medical records and history. Severe dementia will be defined as dementia that impacts daily functioning.) * Patients with severe hepatic impairment. * Patients with end-stage renal disease. * Patients with heart failure. . * Patients with complete gastrointestinal obstruction.
Contact & Investigator
Mark A Preston, MD
PRINCIPAL INVESTIGATOR
Brigham and Women's Hospital
Frequently Asked Questions
Who can join the NCT03216525 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Bladder Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03216525 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 136 participants.
Is NCT03216525 currently recruiting?
Yes, NCT03216525 is actively recruiting participants. Contact the research team at mbarylak@bwh.harvard.edu for enrollment information.
Where is the NCT03216525 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT03216525 clinical trial?
NCT03216525 is sponsored by Brigham and Women's Hospital. The principal investigator is Mark A Preston, MD at Brigham and Women's Hospital. The trial plans to enroll 136 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.